^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Repatha (evolocumab)

    i
    Other names: AMG 145, AMG-145, AMG145
    Company:
    Amgen, Astellas, Dr. Reddy’s
    Drug class:
    PCSK9 inhibitor
    Related drugs:
    4d
    CHORMONE: The relationship of cholesterol-lowering drugs with steroid HORMONEs, bile acids, muscle morphology, vitamin D, the immune system and related diseases such as depression and osteoporosis (2024-516967-10-00)
    P4, N=250, Recruiting, Medical University Of Vienna | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Repatha (evolocumab) • atorvastatin • Praluent (alirocumab)
    1m
    Therapeutic Potential of PCSK9 Inhibitors in Regulating Neuroinflammation in Acute Ischemic Stroke. (PubMed, CNS Drugs)
    Monoclonal antibodies (evolocumab, alirocumab) and small interfering RNA (siRNA) agents (inclisiran) are examples of PCSK9 inhibitors. As a promising multitarget therapeutic strategy for AIS, PCSK9 inhibitors target the interconnected pathways of lipid metabolism and neuroinflammation. Future studies should address critical challenges such as defining the optimal therapeutic time window, improving BBB penetrability, and refining patient stratification to translate their neuroprotective effects into clinical benefits for stroke patients.
    Review • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • TLR4 (Toll Like Receptor 4) • APOE (Apolipoprotein E) • IL1B (Interleukin 1, beta) • CRP (C-reactive protein)
    |
    Repatha (evolocumab) • Praluent (alirocumab)
    1m
    20190184: EVOLVE-MI (2023-509268-26-00)
    P4, N=700, Active, not recruiting, Amgen Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Repatha (evolocumab)
    1m
    Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function. (PubMed, J Clin Lipidol)
    PCSK9 inhibition reduces LpPLA2 and IP-10 without changing global inflammatory response or antioxidant function of HDL, which might indicate a decrease in chronic vascular inflammation without an undesired broad systemic immune alteration.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL10 (Interleukin 10) • CCL2 (Chemokine (C-C motif) ligand 2) • IL17A (Interleukin 17A) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • CRP (C-reactive protein)
    |
    Repatha (evolocumab) • Praluent (alirocumab)
    1m
    Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose (clinicaltrials.gov)
    P1, N=400, Recruiting, Amgen
    New P1 trial
    |
    Repatha (evolocumab)
    2ms
    Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, General Hospital of Shenyang Military Region
    New trial
    |
    Repatha (evolocumab)
    2ms
    EVEREST: Evolocumab in Patients With Multivessel Coronary Disease After Acute Myocardial Infarction: A Target Trial Emulation (clinicaltrials.gov)
    P=N/A, N=1862, Completed, Shanghai Zhongshan Hospital | Active, not recruiting --> Completed | N=912 --> 1862
    Trial completion • Enrollment change
    |
    Repatha (evolocumab)
    2ms
    A Randomized, Open-Label, Blinded Endpoint Evaluation Study of Early Evolocumab Administration in Patients with Atherosclerotic Acute Ischemic Stroke Following Successful Thrombectomy. (ChiCTR2600117460)
    P=N/A, N=60, Recruiting, The Affiliated Hospital of Xuzhou Medical University; The Affiliated Hospital of Xuzhou Medical University, Xuzhou City, Jiangsu Province
    New trial
    |
    Repatha (evolocumab)
    2ms
    A phase IIa, randomized, open-label, blinded endpoint evaluation study of early administration of evolocumab after thrombolysis in patients with atherosclerotic acute ischemic stroke (ChiCTR2500115300)
    P=N/A, N=132, Recruiting, The Affiliated Hospital of Xuzhou Medical University; The Affiliated Hospital of Xuzhou Medical University, Xuzhou City, Jiangsu Province
    New trial
    |
    Repatha (evolocumab) • atorvastatin
    2ms
    Investigation of the impact of Evolocumab on the one-year prognosis in patients with acute coronary syndrome following coronary artery bypass grafting (ChiCTR2500112714)
    P4, N=1518, Recruiting, Beijing Anzhen Hospital, Capital Medical University; Beijing Anzhen Hospital, Capital Medical University
    New P4 trial
    |
    Repatha (evolocumab)
    2ms
    AT-TARGET-IT: Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy (clinicaltrials.gov)
    P=N/A, N=5000, Recruiting, Federico II University | N=2000 --> 5000 | Trial completion date: Mar 2024 --> Mar 2030
    Enrollment change • Trial completion date
    |
    Repatha (evolocumab) • Praluent (alirocumab)
    3ms
    YN001-004 in Patients With Coronary Atherosclerosis in Australia (clinicaltrials.gov)
    P2, N=24, Recruiting, Beijing Inno Medicine Co., Ltd. | N=12 --> 24 | Trial completion date: Sep 2025 --> Jun 2026 | Trial primary completion date: Sep 2025 --> Jun 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Repatha (evolocumab)